Literature DB >> 32184109

Diffusing Capacity Is an Independent Predictor of Outcomes in Pulmonary Hypertension Associated With COPD.

Aparna Balasubramanian1, Todd M Kolb1, Rachel L Damico1, Paul M Hassoun1, Meredith C McCormack1, Stephen C Mathai2.   

Abstract

BACKGROUND: Patients with COPD who experience pulmonary hypertension (PH) have worse mortality than those with COPD alone. Predictors of poor outcomes in COPD-PH are not well-described. Diffusing capacity of the lung (Dlco) assesses the integrity of the alveolar-capillary interface and thus may be a useful prognostic tool among those with COPD-PH. RESEARCH QUESTION: Using a single center registry, we sought to evaluate Dlco as a predictor of mortality in a cohort of patients with COPD-PH. STUDY DESIGN AND METHODS: This retrospective cohort study analyzed 71 COPD-PH patients from the Johns Hopkins Pulmonary Hypertension Registry with right-sided heart catheterization (RHC)-proven PH and pulmonary function testing data within one year of diagnostic RHC. Transplant-free survival was calculated from index RHC. Adjusted transplant-free survival was modelled using Cox proportional hazard methods; age, pulmonary vascular resistance, FEV1, oxygen use, and N-terminal pro-brain natriuretic peptide were included as covariates.
RESULTS: Overall unadjusted transplant-free 1-, 3-, and 5-year survivals were 87%, 60%, and 51%, respectively. Survival was associated with reduced Dlco across the observed range of pulmonary artery pressures and pulmonary vascular resistance. Severe Dlco impairment was associated with poorer survival (log-rank χ2 13.07) (P < .001); adjusting for covariates, for every percent predicted decrease in Dlco, mortality rates increased by 4% (hazard ratio, 1.04; 95% CI, 1.01-1.07).
INTERPRETATION: Among patients with COPD-PH, severe gas transfer impairment is associated with higher mortality, even with adjustment for airflow obstruction and hemodynamics, which suggests that Dlco may be a useful prognostic marker in this population. Future studies are needed to further investigate the association between Dlco and morbidity and to determine the utility of Dlco as a biomarker for disease risk and severity in COPD-PH.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  COPD; mortality; pulmonary diffusing capacity; pulmonary gas exchange; pulmonary hypertension

Mesh:

Year:  2020        PMID: 32184109      PMCID: PMC8173778          DOI: 10.1016/j.chest.2020.02.047

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  63 in total

1.  Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide.

Authors:  Lauren Rose; Kurt W Prins; Stephen L Archer; Marc Pritzker; E Kenneth Weir; Jeffrey R Misialek; Thenappan Thenappan
Journal:  J Heart Lung Transplant       Date:  2018-09-14       Impact factor: 10.247

2.  Discriminative Accuracy of FEV1:FVC Thresholds for COPD-Related Hospitalization and Mortality.

Authors:  Surya P Bhatt; Pallavi P Balte; Joseph E Schwartz; Patricia A Cassano; David Couper; David R Jacobs; Ravi Kalhan; George T O'Connor; Sachin Yende; Jason L Sanders; Jason G Umans; Mark T Dransfield; Paulo H Chaves; Wendy B White; Elizabeth C Oelsner
Journal:  JAMA       Date:  2019-06-25       Impact factor: 56.272

3.  CO transfer capacity as a determining factor of survival for severe hypoxaemic COPD patients under long-term oxygen therapy.

Authors:  P Dubois; J Machiels; F Smeets; J P Delwiche; J Lulling
Journal:  Eur Respir J       Date:  1990-10       Impact factor: 16.671

4.  Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity.

Authors:  V Cottin; H Nunes; P-Y Brillet; P Delaval; G Devouassoux; I Tillie-Leblond; D Israel-Biet; I Court-Fortune; D Valeyre; J-F Cordier
Journal:  Eur Respir J       Date:  2005-10       Impact factor: 16.671

5.  Severe pulmonary hypertension in lung disease: phenotypes and response to treatment.

Authors:  Melanie J Brewis; Alistair C Church; Martin K Johnson; Andrew J Peacock
Journal:  Eur Respir J       Date:  2015-08-20       Impact factor: 16.671

6.  Low DLCO in idiopathic pulmonary arterial hypertension - clinical correlates and prognostic significance.

Authors:  Monika Szturmowicz; Aneta Kacprzak; Monika Franczuk; Barbara Burakowska; Marcin Kurzyna; Anna Fijałkowska; Agnieszka Skoczylas; Stefan Wesołowski; Jan Kuś; Adam Torbicki
Journal:  Pneumonol Alergol Pol       Date:  2016

Review 7.  Pulmonary hypertension in chronic lung diseases.

Authors:  Werner Seeger; Yochai Adir; Joan Albert Barberà; Hunter Champion; John Gerard Coghlan; Vincent Cottin; Teresa De Marco; Nazzareno Galiè; Stefano Ghio; Simon Gibbs; Fernando J Martinez; Marc J Semigran; Gerald Simonneau; Athol U Wells; Jean-Luc Vachiéry
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

8.  "Natural history" of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease.

Authors:  R Kessler; M Faller; E Weitzenblum; A Chaouat; A Aykut; A Ducoloné; M Ehrhart; M Oswald-Mammosser
Journal:  Am J Respir Crit Care Med       Date:  2001-07-15       Impact factor: 21.405

9.  2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung.

Authors:  Brian L Graham; Vito Brusasco; Felip Burgos; Brendan G Cooper; Robert Jensen; Adrian Kendrick; Neil R MacIntyre; Bruce R Thompson; Jack Wanger
Journal:  Eur Respir J       Date:  2017-01-03       Impact factor: 16.671

10.  Haemodynamic definitions and updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; David Montani; David S Celermajer; Christopher P Denton; Michael A Gatzoulis; Michael Krowka; Paul G Williams; Rogerio Souza
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

View more
  4 in total

1.  Ultra-Small Lung Cysts Impair Diffusion Without Obstructing Air Flow in Lymphangioleiomyomatosis.

Authors:  Brianna P Matthew; Amir M Hasani; Yun-Ching Chen; Mehdi Pirooznia; Mario Stylianou; Shirley F Rollison; Tania R Machado; Nora M Quade; Amanda M Jones; Patricia Julien-Williams; Angelo Taveira-DaSilva; Marcus Y Chen; Joel Moss; Han Wen
Journal:  Chest       Date:  2021-02-05       Impact factor: 9.410

2.  Carbon Monoxide Diffusion Capacity as a Severity Marker in Pulmonary Hypertension.

Authors:  Eleni Diamanti; Vasiliki Karava; Patrick Yerly; John David Aubert
Journal:  J Clin Med       Date:  2021-12-27       Impact factor: 4.241

3.  Relevance of Cor Pulmonale in COPD With and Without Pulmonary Hypertension: A Retrospective Cohort Study.

Authors:  Athiththan Yogeswaran; Stefan Kuhnert; Henning Gall; Marlene Faber; Ekaterina Krauss; Zvonimir A Rako; Stanislav Keranov; Friedrich Grimminger; Hossein Ardeschir Ghofrani; Robert Naeije; Werner Seeger; Manuel J Richter; Khodr Tello
Journal:  Front Cardiovasc Med       Date:  2022-02-16

4.  Diffusing capacity in chronic obstructive pulmonary disease assessment: A meta-analysis.

Authors:  Yingmeng Ni; Youchao Yu; Ranran Dai; Guochao Shi
Journal:  Chron Respir Dis       Date:  2021 Jan-Dec       Impact factor: 2.444

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.